insights_auto
Why is GRAL down 10.90%?
Dive Deeperchevron_right
GRAL:NASDAQ
Grail Inc
$137.28
arrow_downward
-10.90%(-16.80) 1D
$135.00
arrow_downward
-1.66% (-2.28)todayPre-market
Closed: Oct 6, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$159.43
High
$166.48
Low
$135.80
Mkt. cap
5.70B
Avg. vol.
1.18M
Volume
3.00K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
Open
$159.43
High
$166.48
Low
$135.80
Mkt. cap
5.70B
Avg. vol.
1.18M
Volume
3.00K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
News stories
From web sources and news partners
Traders Union
·
12 hours ago
Grail stock seen higher on Galleri FDA decision prospects
TipRanks
·
17 hours ago
Insider Sales Trigger Sudden Slide in GRAIL Stock
Stock Titan
·
1 day ago
An officer sold 7,873 shares to cover vesting taxes at GRAIL (NASDAQ: GRAL).
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Joshua Ofman is CEO. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegrail.com